このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ABIONYX Pharma 将来の成長

Future 基準チェック /26

ABIONYX Pharmaの収益は年間18.7%で減少すると予測されていますが、年間収益は年間34.4%で増加すると予想されています。EPS は年間4%で減少すると予想されています。

主要情報

-23.4%

収益成長率

-13.8%

EPS成長率

Biotechs 収益成長	10.9%
収益成長率	40.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	27 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

ENXTPA:ABNX - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	12	-7	-7	-7	1
12/31/2025	7	-9	-9	-9	1
12/31/2024	5	-6	-6	-6	1
6/30/2024	5	-3	-3	-3	N/A
3/31/2024	5	-3	-3	-3	N/A
12/31/2023	5	-4	-4	-4	N/A
9/30/2023	5	-4	N/A	N/A	N/A
6/30/2023	5	-4	-2	-2	N/A
3/31/2023	5	-4	-3	-3	N/A
12/31/2022	5	-4	-4	-3	N/A
9/30/2022	4	-5	N/A	N/A	N/A
6/30/2022	3	-6	-6	-6	N/A
3/31/2022	2	-6	-6	-6	N/A
12/31/2021	1	-6	-7	-7	N/A
9/30/2021	0	-5	N/A	N/A	N/A
6/30/2021	0	-4	-6	-5	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	0	0	N/A
3/31/2020	N/A	0	-2	-2	N/A
12/31/2019	N/A	2	-4	-4	N/A
9/30/2019	0	1	-5	-5	N/A
6/30/2019	0	0	-6	-6	N/A
3/31/2019	0	-3	-6	-6	N/A
12/31/2018	0	-6	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	N/A	-8	-7	-7	N/A
3/31/2018	N/A	-6	N/A	-8	N/A
12/31/2017	N/A	-5	N/A	-9	N/A
9/30/2017	N/A	-8	N/A	-11	N/A
6/30/2017	N/A	-11	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-25	N/A	-19	N/A
9/30/2016	N/A	-25	N/A	-19	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-20	N/A	-16	N/A
12/31/2015	N/A	-17	N/A	-14	N/A
9/30/2015	N/A	-13	N/A	-11	N/A
6/30/2015	N/A	-10	N/A	-8	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABNX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ABNX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ABNX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ABNXの収益 ( 34.4% ) French市場 ( 5.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: ABNXの収益 ( 34.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABNXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ABIONYX Pharma 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to €0.14 loss

Consensus EPS estimates upgraded to €0.18 loss

Consensus EPS estimates upgraded to €0.23 loss

Price target increased to €5.50

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Recent updates

Consensus EPS estimates upgraded to €0.14 loss

First half 2024 earnings released

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

New minor risk - Share price stability

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Consensus EPS estimates upgraded to €0.18 loss

Consensus EPS estimates upgraded to €0.23 loss

First half 2023 earnings released

New minor risk - Shareholder dilution

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

Price target increased to €5.50

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Consensus revenue estimates fall by 22%

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

Price target increased to €4.30

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

Investor sentiment improved over the past week

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

Investor sentiment improved over the past week

New 90-day low: €0.84

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

Investor sentiment improved over the past week

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

New 90-day high: €1.11

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

New 90-day low: €0.72

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘